Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Will Generics Take Off? (3)
May 19, 2008
- NEW PRODUCT／Sanofi-aventis: Clexane Kit for SC Injection
May 19, 2008
- Nippon Shinyaku Licenses PAH Treatment to Actelion
May 5, 2008
- Council Proposes Introduction of "Emergency Budgets for National Projects" in FY2009
May 5, 2008
- Astellas Licenses BACE Inhibitors from CoMentis
May 5, 2008
- R&D NEWS IN BRIEF
May 5, 2008
- Kyorin Licenses Flutiform from SkyePharma
May 5, 2008
- Will Generics Take Off? (2)
May 5, 2008
- Kyowa Hakko Licenses Antibody for Cancer from Arana of Australia
May 5, 2008
- A Saisei-kai Hospital Decides Not to Use Generics as a Rule
May 5, 2008
- DSP to Copromote Lonasen with Yoshitomi to Quickly Develop Market
May 5, 2008
- President Hatori Shows Confidence in Vigorous Growth of SSP from FY2009
May 5, 2008
- More APIs, Intermediates to Become Duty-Free
May 5, 2008
- SELF-MEDICATION NEWS IN BRIEF
May 5, 2008
- Chugai Revises Business Forecast Upward for 2008 due to Lower-than-expected NHI Price Revisions
May 5, 2008
- GENERICS NEWS IN BRIEF
May 5, 2008
- New JPMA President from Daiichi Sankyo?
May 5, 2008
- Carotid Artery Stenting Improves QOL: J&J Seminar
May 5, 2008
- Palliative Care Needed from Initial Stage of Cancer Treatment
May 5, 2008
- Nexavar to Be Transiently Excluded from DPC System
May 5, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…